Latest News for: tlr9

Edit

Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma

PR Newswire 22 Jan 2024
... to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.
Edit

Immunitas Therapeutics Presents New Data For TLR9 Agonist Conjugate At The Society For Immunotherapy Of ...

MENA FN 03 Nov 2023
(MENAFN - PR Newswire) In vitro proof-of-concept data shows effective delivery of CpG to endosomal TLR9 via anti CLEC2D antibody, resulting in sustained myeloid and B cell activation, enabling ... .
Edit

Immunitas Therapeutics Presents New Data for TLR9 Agonist Conjugate at the Society for Immunotherapy of Cancer 2023 Annual Meeting

PR Newswire 03 Nov 2023
In vitro proof-of-concept data shows effective delivery of CpG to endosomal TLR9 via anti CLEC2D antibody, resulting in sustained myeloid and B cell activation, enabling induction of stronger T cell responses.
Edit

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy ...

Longview News-Journal 31 Oct 2023
Anti CLEC2D-TLR9 agonist conjugate binds to and internalizes CLEC2D on myeloid cells, plasmacytoid DCs and B cells leading to robust TLR pathway activation and inflammatory cytokine production.
Edit

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting

PR Newswire 31 Oct 2023
In vitro proof-of-concept for novel myeloid and B cell modulating anti-CLEC2D-TLR9 agonist conjugate program, a compelling immunotherapeutic approach to induce T and NK cell recruitment in tumors with otherwise low immunological activity.
  • 1

Most Viewed

×